NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Scholar Rock Holding Corp. SRRK
9 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
—
Revenue, FY2025 · full 9-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.0 · Net income -377.9
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2022 · Operating -404.8% · Net -405.2%
ROE
FY2025 · ROE -123.1%
Each USD of equity lost 123 cents this year.
The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Operating income $B | −0.4 | −0.3 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 |
| EBITDA $B | · | · | · | · | · | · | · | · | · |
| Income tax $B | · | · | · | · | · | · | · | · | · |
| Net income $B | −0.4 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| Free cash flow $B | −0.3 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | 0.0 | −0.0 |
| EPS, diluted $ | −3.29 | −2.47 | −1.99 | −2.26 | −3.59 | −2.81 | −1.85 | −3.15 | −15.30 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · |
| ROE % | −123.1 | −82.9 | −68.3 | −62.2 | −60.9 | −46.3 | −46.5 | −185.8 | · |
| Shares out B | 0.11 | 0.09 | 0.08 | 0.05 | 0.04 | 0.03 | 0.03 | 0.03 | 0.00 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 36 reconciliationsAUDITED
Reconciled in 9 of 19 fiscal years. 40 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2017